MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. The cells are cross-resistant to melphalan but show little or no cross-resistance to other platinum compounds. Cisplatin accumulation has been found to be reduced compared to the parent line.